---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-24-000043"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:08:40.467153+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme beats Q2 with $231M revenue, $0.91 non-GAAP EPS; reiterates raised 2024 outlook

## Summary
- Revenue $231M (+5% YoY), net income $93M (+24%), GAAP EPS $0.72, non-GAAP EPS $0.91.
- Royalty revenue $124.9M (+12% YoY) led by Phesgo, VYVGART Hytrulo, and Teriparatide launches.
- Reiterated FY2024 guidance: rev $935-1015M, adj EBITDA $555-615M, non-GAAP EPS $3.65-4.05.
- Partner approvals: Ocrevus SC (EU/UK), VYVGART Hytrulo for CIDP (US); BMS nivolumab SC PDUFA Dec 29, 2024.
- Completed $250M ASR (6.5M shares at $38.35); new EU patent extends ENHANZE royalty through March 2029.

## SEC filing metadata
- accession: 0001159036-24-000043
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000043/0001159036-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000043/halo-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-24-000043
- JSON: https://secwatch.observer/filing/0001159036-24-000043.json
- Plain text: https://secwatch.observer/filing/0001159036-24-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.